BEDFORD, MA—Ticho Barry, the Chief Medical (TASE:PMCN) Officer of Stoke Therapeutics, Inc. (NASDAQ:STOK), recently reported a sale of company stock valued at $120,698. The transaction comes as the stock has shown remarkable strength, gaining over 205% in the past year according to InvestingPro data. The transaction involved the sale of 10,000 shares, executed on December 2, 2024, at a weighted average price of $12.0698 per share. The sale was conducted under a pre-established Rule 10b5-1 trading plan. Notably, InvestingPro analysis shows the company maintains a strong financial position with a current ratio of 5.09, indicating robust liquidity. Analysts maintain a positive outlook, with price targets ranging from $15 to $35.
In addition to the sale, Barry also reported two acquisitions of common stock through option exercises. On December 1, 2024, Barry acquired 48,792 shares at no cost, and on December 2, 2024, he acquired an additional 10,000 shares at $0.60 per share. These acquisitions were part of previously awarded restricted stock units and stock options.
Following these transactions, Barry's total direct ownership stands at 51,277 shares.
In other recent news, Stoke Therapeutics continues to make significant strides in its clinical trials and corporate affairs. The company's lead product candidate, zorevunersen, has shown promising results in treating Dravet syndrome, a severe form of epilepsy. This investigational therapy, which has shown cognitive and behavioral improvements in patients, is now being prepared for pivotal Phase 3 trials. The positive results from the ongoing Phase 1/2a and Open Label Extension (OLE) studies have been well received by analysts, with TD Cowen maintaining its Buy rating for Stoke Therapeutics.
Furthermore, Stoke Therapeutics has also resolved a director compensation dispute. The settlement, which includes a mootness fee of $175,000 and an agreement to pay up to $415,000 in attorney's fees and expenses, follows a shareholder derivative lawsuit alleging excessive director compensation and misleading disclosures. As part of the settlement, Stoke Therapeutics has committed to maintain certain director compensation policy changes.
These developments, including the promising clinical trial data and the resolution of the corporate dispute, highlight Stoke Therapeutics' recent progress. As the company prepares to advance zorevunersen into Phase 3 trials and continues to navigate its corporate affairs, investors and industry observers will be closely monitoring these developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.